Furthermore, in the FOENIX-CCA2 (NCT02052778) trial, a single-arm multicenter phase two study evaluating the activity of futibatinib in CCA patients with FGFR2 gene fusions experiencing disease progression after standard treatments (including gemcitabine plus platinum-based chemotherapy) [26] emerged an impressive RR of 34.3% in 67 of the cases enrolled. Here, FGFR2 is linked to cholangiocarcinoma.